https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16766 Wed 11 Apr 2018 15:18:46 AEST ]]> An immune atlas of clear cell renal cell carcinoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34616 Thu 04 Nov 2021 10:39:12 AEDT ]]> Norcantharidin induces HT-29 colon cancer cell apoptosis through the αvβ6-extracellular signal-related kinase signaling pathway https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7110 Sat 24 Mar 2018 08:34:09 AEDT ]]> Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25708 Sat 24 Mar 2018 07:28:18 AEDT ]]> Surgical management of transitional cell carcinoma of the lacrimal sac: is it time for a new treatment algorithm? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23477 Sat 24 Mar 2018 07:09:30 AEDT ]]> Carcinoma of the male breast in Zambia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34163 female follows the general trend of lowered incidence of carcinoma of the breast for Africa, the male shows an unexpected increased incidence. Some of the possible aetiological factors have been superficially examined but no facts have been established yet to account for the relatively high male incidence.]]> Mon 23 Sep 2019 13:45:06 AEST ]]> Granuloma venereum https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34153 Mon 23 Sep 2019 13:38:24 AEST ]]> Schistosomiasis and carcinoma of the bladder in Zambia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34177 Mon 23 Sep 2019 11:35:16 AEST ]]> Strategies to promote screening for cancer of the uterine cervix https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37090 Fri 14 Aug 2020 14:41:47 AEST ]]> Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41264 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). The reduction was larger in the first 5 years (35 vsvsvs 70, HR 0·96, 95% CI 0·69–1·34, p=0·82) or for breast cancer (two anastrozole vs three placebo). A significant decrease in non-breast cancers was observed for anastrozole (147 vs 200, odds ratio 0·72, 95% CI 0·57–0·91, p=0·0042), owing primarily to non-melanoma skin cancer. No excess of fractures or cardiovascular disease was observed. Interpretation: This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects. Further follow-up is needed to assess the effect on breast cancer mortality.]]> Fri 11 Aug 2023 16:56:23 AEST ]]>